Glenmark Life Sciences IPO GMP History
Glenmark Life Sciences IPO has been listed on August 6, 2021 at a listing price of ₹750, against the issue price of ₹720 — a gain of ₹30 (+4.17%). The GMP peaked at ₹280 on 21 July 2021 and reached a low of ₹130 on 31 July 2021. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Glenmark Life Sciences IPO raised ₹1513.6 Cr. through its IPO at a price band of ₹695 to ₹720 per share, with a lot size of 20 shares. The IPO was open for subscription from 27 Jul 2021 to 29 Jul 2021.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 7:18 AM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 31 Jul 2021 | ₹ 130 | ▼ | 18% | — | — |
| 30 Jul 2021 | ₹ 150 | — | 21% | — | — |
| 29 Jul 2021 | ₹ 150 | — | 21% | — | — |
| 28 Jul 2021 | ₹ 150 | ▼ | 21% | — | — |
| 27 Jul 2021 | ₹ 170 | ▼ | 24% | — | — |
| 26 Jul 2021 | ₹ 220 | ▼ | 31% | — | — |
| 23 Jul 2021 | ₹ 250 | — | 35% | — | — |
| 22 Jul 2021 | ₹ 250 | ▼ | 35% | — | — |
| 21 Jul 2021 | ₹ 280 | — | 39% | — | — |
Glenmark Life Sciences IPO dates
Key dates from opening to listing. Today is 10 November.
- Open 27 Jul 2021
- Close 29 Jul 2021
- Allotment 03 Aug 2021
- Refund/credit 04 Aug 2021
- Listing 06 Aug 2021
Glenmark Life Sciences IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹720 |
|---|---|
| GMP-based estimate (pre-listing) | ₹850 (+18.1%) |
| Listing gain / loss | +₹30 per share |
| Listing date | 06 Aug, 2021 |
| Actual listing price | ₹750 (+4.17%) |
Is Glenmark Life Sciences IPO GMP reliable?
Grey market premium for Glenmark Life Sciences IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Glenmark Life Sciences IPO full review for a fundamentals-based assessment before making any grey market trades.
Glenmark Life Sciences IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Glenmark Life Sciences IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Glenmark Life Sciences IPO
Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited at Pune on 23 June 2011. It became a wholly owned subsidiary of Glenmark Pharmaceuticals on 10 July 2018, and Glenmark's API business was spun off into it on 1 January 2019.
It develops, makes and supplies APIs for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders and anti-infectives. It also offers contract development and manufacturing services to specialty pharma companies.
It sells in India and exports to Europe, North America, Latin America and Japan. It has 4 plants, at Ankleshwar and Dahej in Gujarat and at Mohol and Kurkumbh in Maharashtra, with an installed capacity of 725.8 KL on 31 December 2020.
The IPO was Rs 1,513.60 crore, with Rs 1,060.00 crore of fresh issue and Rs 453.60 crore of offer for sale by Glenmark Pharmaceuticals. Rs 800.00 crore of the fresh issue was planned for paying the promoter the outstanding consideration for the API business spin-off.
Frequently asked
What is the GMP of Glenmark Life Sciences IPO?
The current Grey Market Premium (GMP) of Glenmark Life Sciences IPO is ₹ 130.
What is the Kostak Price of Glenmark Life Sciences IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Glenmark Life Sciences IPO is not available.
What is the Subject to Sauda Price of Glenmark Life Sciences IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Glenmark Life Sciences IPO?
Glenmark Life Sciences IPO listed on August 6, 2021 at ₹750, against the issue price of ₹720 — a gain of +4.17%.
How did the GMP of Glenmark Life Sciences IPO trend before listing?
The GMP of Glenmark Life Sciences IPO was falling in its final days before listing. The GMP peaked at ₹280 on 21 July 2021. View the day-wise table above for the complete GMP history.
Explore Glenmark Life Sciences IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
